Iovance (IOVA) Interim CEO Frederick Vogt Receives 15,626 Shares

What Happened

• Frederick G. Vogt, Interim CEO & General Counsel and a director of Iovance Biotherapeutics (IOVA), had 15,626 restricted stock units (RSUs) convert to common stock on Sep 8, 2026. The conversion is reported as the exercise/conversion of a derivative at $0.00 per share.
• The issuer withheld 6,638 shares to satisfy mandatory tax withholding at an implied value of $8.70 per share (total $57,751). After withholding, 8,988 shares remained issued to Mr. Vogt.
• This was vesting/award activity (receipt of shares), not an open-market sale.

Key Details

• Transaction date: 2026-09-08; Form 4 filed: 2026-09-10 (appears timely).
• Conversion: 15,626 RSUs -> 15,626 shares at $0.00 per share (derivative conversion).
• Tax withholding: 6,638 shares withheld at $8.70/share = $57,751 (not an open-market sale).
• Shares remaining after withholding: 8,988 common shares.
• Notable footnotes: RSUs vested on the transaction date (each RSU = 1 share); withheld shares satisfy mandatory tax withholding and are not sales; remaining RSUs vest in equal quarterly installments; the aggregate reflects the remainder of RSUs granted March 5, 2025.

Context

• This was a vesting/conversion of RSUs (award), not a purchase or an open-market sale. Tax-withholding via share retention is routine and does not signal an active sale by the insider.
• For retail investors: awards/vesting increase insider holdings but are generally compensation-related rather than a direct bullish bet by management.